Where do Biopharma industries lie at the current time?

Where do Biopharma industries lie at the current time?

Hi readers!!!

First, let me introduce myself. I am Bismita from Assam, India, and currently working for a biopharmaceutical company located in Bengaluru. Today I would like to share how I ended up being a bio-techie and provide some insights into the company I am working for. I landed up taking Biotechnology as my Graduate course because of my craze to learn Biology & life sciences. I was keen to know how the system of nature works. So, I thought the best way to opt for that was getting into medics which I couldn’t so I opted for Biotechnology as my core subject in my Bachelor degree. Never did I know how vast biotechnology would be. The more I dive into the subject, the lesser I feel I have known. I like the fact that this subject has its branches spreading everywhere, having vast areas covered within it and is not limited to a few.

So, moving forward to what we are doing at Biocon Biologics. It is a subsidiary of the company Biocon where we are working for the manufacturing of Biologics. Biologics are potential medications comprised of components like sugars, proteins, or DNA, it can be whole cells or tissues. These types of medicines contain substances that are made by living cells or organisms. They are usually made up of proteins that are produced in the human body naturally. When these drugs are administered to a patient, they function as the natural protein, resolving symptoms and preventing or slowing the progression of the disease.

Biocon has a total of 5 manufacturing facilities across the country and 1 manufacturing facility overseas (Malaysia) where it manufactures multiple products like Generics, Biosimilars, Branded formulation, and novel Biologics. Biocon Biologics has one of the largest global Biosimilars portfolios spanning different types of Biosimilars like recombinant human Insulin (RH-Insulin), insulin analogs, monoclonal antibodies (mAbs), and other biologics for oncology, immunology, and other therapeutic areas.Currently, My arena of working is MSAT (Manufacturing Sciences and Technology) which supports the manufacturing of Biosimilars (Monoclonal antibodies)with scale up, scale down, tech transfers, process validations, deviations, impact assessment, risk assessment, and many more. MSAT department functions as a bridge between RND and Manufacturing.In these current times, we are continuously working to meet the demands of the patients, partners, business without a pause in manufacturing.

In Biocon Biologics, we have various functions working simultaneously to meet the same goal: one and only “Patient eccentricity”. Our main focus is to meet the patient requirements as the demand for pharmaceuticals raises with enhanced life expectancy, rising affordability, and improved living standards. One of the very important motos of the company is to make life-saving drugs more affordable and accessible for patients which can help them to live a prolonged and quality life.

With the sudden surge in covid-19, the Biotech industries in India are tremendously increasing with higher market demands for the production of vaccines, drugs, diagnostic kits, etc along with the research & development sector. It gives ample opportunities for the Bio-techies who are looking for jobs in industries and labs.

We are happy to inform you that during the COVID-19 situation, our company was able to contribute in many ways like,

  • Introduction of the novel biologic ALZUMAb® (Itolizumab) for COVID-19 patients. It is an anti-CD-6 IgG1 monoclonal antibody, which has shown promising results in treating cytokine release syndrome (CRS) in COVID-19 patients experiencing acute respiratory distress syndrome (ARDS).

  • Biocon Biologics has been supplying CytoSorb 300 ®, a device that reduces cytokine storms in critically ill patients. The Company has received the Drugs Controller General of India’s (DCGI) approval for this extracorporeal blood purification (EBP) device to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to intensive care unit (ICU) with confirmed or imminent respiratory failure.

  • Syngene (A subsidiary of Biocon) has set up a COVID-19 testing facility in a record time and a dedicated team of specially trained scientists has been analyzing samples from all over the state with RT-PCR analysis.

  • Syngene has also developed an ELISA kit that is reported to be highly reliable and identifies the presence of SARS-COV-2 antibodies in blood samples and confirms if a patient has been exposed to the coronavirus.

  • Biocon Foundation has been serving the underprivileged and addressing the needs of daily wage earners and migrant laborers affected by the economic fallout of the COVID-19 crisis.

With the rapid advancement in technology and constant development of drugs & vaccines, I believe biotechnology will stand out to cure more and more people and save lives because every single life matters.
Happy Reading!!! Until next time.

Reference:
Biocon Clinical Study

Comments